Retrotope announced today that it has fully enrolled all patients in the first clinical trial of a possible treatment for infants with the ultra-rare neurodegenerative disease, Infantile Neuroaxonal Dystrophy (INAD). The U.S. Food and Drug Administration (FDA) has...
DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the first patients have been treated in its...
Retrotope announced today that it has fully enrolled all patients in the first clinical trial of a possible treatment for infants with the ultra-rare neurodegenerative disease, Infantile Neuroaxonal Dystrophy (INAD). The U.S. Food and Drug Administration (FDA) has...
Eureka Therapeutics has initiated a phase 1/2 clinical trial of its ET140202 Artemis T-cell therapy for the treatment of liver cancer, according to a press release. The company will evaluate ET140202 in combination with its Artemis antibody T-cell receptor platform...
AstraZeneca and Merck’s LYNPARZA Improved Radiographic Progression Free Survival vs. Standard of Care in Patients Selected for BRCA 1/2 or ATM Mutations Only PARP Inhibitor with Positive Phase 3 Results in Four Different Cancer Types AstraZeneca and Merck (MRK), known...
– Rimegepant is the only oral CGRP receptor antagonist currently in development for both the acute and preventive treatment of migraine – Over 1,600 patients have been enrolled in this Phase 3 preventive treatment of migraine trial with rimegepant and...
Email
Text